Sarclisa, multiple myeloma and European Medicines Agency
EMA human medicine committee recommends approval of Sanofi’s Sarclisa to treat transplant-ineligible newly diagnosed multiple myeloma
EMA human medicine committee recommends approval of Sanofi’s Sarclisa to treat transplant-ineligible newly diagnosed multiple myeloma: Paris Saturday, November 16, 2024, 09:00 H
The drugmaker has won an appeal against NICE's recent final draft guidance on Sarclisa (isatuximab) as a regimen alongside ...
J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...
Zacks.com on MSN1mon
Sanofi's Sarclisa Gets FDA Nod for Expanded Use in Multiple MyelomaFollowing this approval, Sarclisa is the first anti-CD38 therapy in combination with VRd for treating transplant-ineligible ...
Sanofi's Sarclisa has been an also-ran in the anti-CD38 antibody class behind Johnson & Johnson and Genmab's blockbuster Darzalex, but now has a chance to steal some of the spotlight. The FDA has ...
In September, commenced patient dosing to investigate evorpacept plus SARCLISA® (isatuximab-irfc) and dexamethasone in ...
Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback